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Abstract
Introduction:  The association of systemic lupus erythematosus with malignancies is an
uncommon occurrence. We present the case of an osteosarcoma of the urinary bladder developing
in a patient with a prolonged history of active systemic lupus erythematosus. This is a previously
unreported association. Primary osteosarcoma is an extremely rare disease in the urinary bladder.
Case presentation: A 24-year-old Caucasian woman with a 13-year history of systemic lupus
erythematosus, who had been treated with high dose immunosuppressive agents, presented with
pain and hematuria. A deeply invasive high-grade tumor was detected in the urinary bladder and
the patient underwent radical surgery. A diagnosis of osteosarcoma was made based on the
characteristic histology.
Conclusion:  Predisposing factors for primary sarcomas in the urinary bladder are mostly
unknown; however, in our case, long-term administration of immunosuppressive agents, as well as
long standing systemic lupus erythematosus, may both be of significance.
Introduction
In this report, we present the case of a 24-year-old woman
with a primary osteosarcoma of the urinary bladder.
Malignant mesenchymal tumors comprise less than
0.04% of urinary bladder malignancies [1]. The most fre-
quent histology is rhabdomyosarcoma in children and lei-
omyosarcoma in the older age group. In the English
language medical literature, only 30 cases of primary oste-
osarcoma of the urinary bladder have been reported to
date. Our case, being the 31st, is unique in respect to the
patient's age and the history of systemic lupus erythema-
tosus (SLE), which appears as a possible predisposing fac-
tor. The patient had been treated with
immunosuppressive medications including cyclophos-
phamide for active SLE for many years. Neoplastic trans-
formations in SLE are accepted as occurring more
frequently than in the general population [2];most
tumors are lymphomas with sarcomas being exceptional
and, to our knowledge, no previous cases of osteosar-
coma, in any location in the body, accompanying SLE,
have been reported.
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Case presentation
We first saw our patient in 1995 when she was an 11-year-
old girl and she presented with fever, fatigue, loss of appe-
tite, malar rash and swelling in the small joints of her
hands. Laboratory investigations at that time revealed ele-
vated antinuclear antibody titer (1/1000) and anti-dsDNA
levels (124 IU/mL), anemia, decreased C3 (14.3) and C4
(8.1) and SLE was diagnosed. She was treated with azathi-
oprine 100 mg for 3 months, hydroxychloroquine 400 mg
for 9 months and prednisolone 10–32 mg daily. Her dis-
ease was in remission for 2 years. In December 1997,
cyclophosphamide (50–150 mg/day) was added and
hydroxychloroquine was restarted because of flare up of
the SLE activity with direct Coombs positive hemolytic
anemia and elevated sedimentation rate. Thereafter, there
was no complete remission and she was continuously on
immunosuppressive medications, with the dose regula-
tions depending on her white blood cell count, and she
also needed pulse methylprednisolone administration
once a month. She also had frequent urinary tract infec-
tions with Gram negative bacteria which were treated with
several antibiotics.
In November 2007, she presented again complaining of
flank pain and bloody urine. Ultrasonogram revealed left-
sided hydronephrosis and dilatation of the left ureter and
a nephrostomy catheter was placed in her left renal pelvis.
Cystoscopic examination was performed and a polypoid
lesion in the bladder obstructing the left ureteral orifice
was observed. Computerized tomography (CT) of the pel-
vis indicated diffuse thickening of the bladder wall
throughout the organ and obscured fat planes between
the bladder and uterus, arousing suspicion of perivesical
tissue invasion by a malignancy (Figures 1a and 1b).
Biopsy with transurethral resection of the tumor showed
a high-grade pleomorphic sarcoma infiltrating widely in
mucosa and muscularis propria. A CT scan of her chest
was unremarkable and a bone scan showed no evidence
of metastatic disease in her skeleton. A radical cystectomy
plus bilateral pelvic lymphadenectomy, total hysterec-
tomy and anterior vaginectomy were performed with ileal
conduit urinary diversion.
On macroscopic examination of the radical cystectomy
specimen, a large ulcerating exophytic polypoid nodular
tumor, mainly located on the left lateral and posterior
walls of the urinary bladder, was observed. It extended
from the dome down to the urethra, involving the trigone
and bladder neck plus both ureteral orifices, as well as the
right lateral and anterior walls distally (Figure 2). It was a
shiny gray to white infiltrative firm mass with areas of sof-
tening and necrosis. The tumor had invaded the whole
thickness of the bladder wall and penetrated into the
perivesical fat tissue, as well as the anterior wall of the
vagina. The rest of the bladder mucosa was hemorrhagic
Computed tomography Figure 1
Computed tomography. Unenhanced (a) and enhanced 
(b) CT of pelvis showing diffuse extensive thickening of blad-
der wall.
Macroscopic appearance of the tumor; (b) shows a horizon- tal slice taken from the body of bladder Figure 2
Macroscopic appearance of the tumor; (b) shows a 
horizontal slice taken from the body of bladder.Journal of Medical Case Reports 2009, 3:39 http://www.jmedicalcasereports.com/content/3/1/39
Page 3 of 5
(page number not for citation purposes)
and ulcerated. Microscopically, a highly cellular neoplasm
composed of pleomorphic spindle or plump cells with a
variable amount of eosinophilic cytoplasm was seen.
Neoplastic cells formed large areas of malignant cartilage
and lacelike osteoid in addition to short interlacing fasci-
cles (Figure 3). There were also occasional osteoclastic-
type multinucleated giant cells and the mitotic rate was in
excess of 20 per 10 high-power fields. Lymphovascular
invasion and large areas of necrosis were also common
and the tumor extended to the resection margin at the dis-
tal posterior border of the specimen. Immunohistochem-
ical stains performed on the paraffin-embedded material
showed no reaction for pan-cytokeratin, cytokeratin 7,
cytokeratin 20, p63 or epithelial membrane antigen
(EMA) (Figure 4). There was strong p53 nuclear staining
in more than 90% of the neoplastic cells and extensive
sampling of the rest of the bladder revealed neither papil-
lary urothelial neoplasm nor flat carcinoma in-situ or epi-
thelial dysplasia. The uterus was unremarkable and the
bilaterally dissected pelvic lymph nodes showed reactive
lymphoid hyperplasia without metastasis. Based on the
morphology and negative immunohistochemical staining
with epithelial markers, in addition to the clinical absence
of another tumor focus elsewhere in the body, a diagnosis
of primary osteosarcoma of the urinary bladder was
made. There was no evidence of recurrence or metastasis
6 months after surgery.
Discussion
Primary sarcomas of the urinary bladder are uncommon
[1] and most originate from muscle as rhabdomyosar-
coma which is dominant in children, whereas leiomyosa-
rcoma is dominant in adults. There are only 30 published
cases of primary osteosarcoma of the urinary bladder in
the literature [3-5] and they show a male to female ratio
of 4:1. The age of the patients ranges from 41 to 86 years
(mean 64 years) and the most common presentation is
hematuria. The tumors are large, polypoid and deeply
infiltrative and the most common single location is the
trigone where histology shows a high-grade sarcoma with
osteoid production. The differential diagnosis includes
many possibilities, including: 1) sarcomatoid variant of
urothelial carcinoma; 2) urothelial carcinoma with
osseous metaplasia and; 3) carcinoma with pseudosarco-
matous stromal reaction. Primary sarcomas of the urinary
bladder including leiomyosarcoma, chondrosarcoma,
rhabdomyosarcoma, angiosarcoma and malignant
fibrous histiocytoma as well as osteosarcoma are much
more rare than sarcomatoid urothelial carcinoma. The
diagnosis of a sarcoma should only be made after exclud-
Low (a) and high power (b) pictures of the sarcoma Figure 3
Low (a) and high power (b) pictures of the sarcoma. 
Highly pleomorphic cellular tumor is seen with areas of oste-
oid (indicated by arrow) and chondroid (indicated by asterix) 
formations. Non-neoplastic surface epithelium overlying the 
tumor is apparent in part (a). Osteoclast-type multinucleated 
giant cells are seen scattered among malignant cells, seen in 
part (b). (a: H-E × 40; b: H-E × 200).
Immunohistochemistry Figure 4
Immunohistochemistry. a) Neoplastic cells do not 
express cytokeratins. Normal urothelium constitutes the 
positive intrinsic control of the stain (Primary anti-pancytok-
eratin Ab, ABC × 100). b) Diffuse and strong p53 positivity 
by the neoplasm (Primary anti-p53 Ab, ABC × 200).Journal of Medical Case Reports 2009, 3:39 http://www.jmedicalcasereports.com/content/3/1/39
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ing all these possibilities. A prior history of urothelial car-
cinoma may provide sufficient evidence for a
mesenchymal-looking malignancy as being in fact a sarco-
matous carcinoma even though there may not be an epi-
thelial component at the time. The immunohistochemical
profile of a sarcomatoid carcinoma notably includes pos-
itivity for epithelial markers, cytokeratins or epithelial
membrane antigen at least focally. However, a positive
reaction does not necessarily exclude mesenchymal origin
as it is well known that some sarcomas such as malignant
fibrous histiocytoma and leiomyosarcoma can co-express
epithelial antigens. Furthermore, occasional sarcomatoid
carcinoma can be completely negative for any epithelial
marker applied. Features that are helpful in making a deci-
sion towards carcinoma include identification of nested
or clustered epitheloid tumor cells, of either conventional
or other types of carcinoma, lying adjacent to sarcomatoid
cells. The presence of in-situ carcinoma is also another
supporting feature for epithelial origins. In our case, the
histology of the bladder tumor was identical to osteosar-
coma of the bone with characteristic formation of lace-
like osteoid in between malignant cells, as well as an
abundant chondroid matrix. No past or accompanying
urinary epithelial malignancy was identified; immunohis-
tochemistry did not demonstrate epithelial differentiation
and all these findings supported a diagnosis of primary
vesical osteosarcoma.
Our current presentation is the first case report of osteosa-
rcoma in a patient with SLE. It has been stated that malig-
nant neoplasms occur more commonly in patients with
SLE than in the general population [2]. Cohort studies
have yielded varying estimates of the relative cancer risk in
SLE, most with fairly wide confidence intervals (CIs). The
standardized incidence ratios in these studies ranged from
1.1 (95% CI 0.7–1.6) to 2.6 (95% CI 1.5–4.4) and the risk
of non-Hodgkin lymphoma in SLE has been found to be
increased 3–4-fold compared with the risk in individuals
without SLE [6]. Several types of sarcomas have been
observed in SLE, including leiomyosarcoma, Kaposi sar-
coma, angiosarcoma and liposarcoma [6-9]. Numerous
pathogenic mechanisms have been proposed although
hypotheses regarding the specific reasons still remain
largely speculative since this issue has not yet been well
studied. Patients with SLE have defects in both their cellu-
lar and humoral immune systems and prolonged stimula-
tion of B lymphocytes, together with defective immune
surveillance, could result in the formation of autonomous
B-cell clones and result in lymphoma development.
Another possible pathogenic link between SLE and cancer
include immunosuppressive treatments.
Our patient had a long history of SLE with her disease
being constantly active for 13 years and she was continu-
ously on high dose steroids and cyclophosphamide to
achieve immunosuppression. Several groups have
described primary leiomyosarcoma in the urinary bladder
where patients had been exposed to cyclophosphamide
for either neoplastic or non-neoplastic conditions
[10,11]. Three of those cases were SLE patients, one of
which was Epstein-Barr virus associated.
Cyclophosphamide is a commonly used chemotherapeu-
tic and immunosuppressive medication. It is a direct
alkylating agent, activated after intake in the liver by cyto-
chrome P-450, and the associated metabolites are excreted
in the urine. The bladder cancer risk is increased 6.8-fold
in cyclophosphamide-exposed patients, ranging from 6.4
in the absence of cystitis to 11.3 when hemorrhagic cysti-
tis is present [11,12]. The carcinogenic action is thought to
be secondary to urinary excretion of acrolein, one of the
metabolites of cyclophosphamide [10-12]. It has been
noted that the relative proportion of mesenchymal neo-
plasms over urothelial malignancies in the urinary blad-
der is increased with exposure to this drug.
Leiomyosarcomas represent 9.2% of bladder tumors in
patients exposed to cyclophosphamide compared with
0.1% of sporadic tumors [10].
An additional contributing factor for the increased risk of
bladder neoplasia in our case could be the frequent uri-
nary tract infections. The patient suffered from recurrent
urinary infections due to Gram negative bacteria. Produc-
tion of carcinogenic nitrites from urinary nitrates by Gram
negative bacteria is highly suspected in the etiology of
tumor formation.
The prognosis for vesical osteosarcoma is usually dismal
with 22 out of 25 patients dying within 6 months, most as
a result of local spread with urinary tract obstruction and
secondary infections. Distant metastases are uncommon.
Conclusion
We recommend that periodic evaluation of SLE patients
who have been on heavy immunosuppressive therapy,
especially with cyclophosphamide, should include exclu-
sion of malignancies. Particular attention must be paid to
the urinary bladder, also taking into account the possibil-
ity of uncommon histological tumor types.
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